Jul 25,2023

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Glucotrack, a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could reliably report glucose measurements for two years post-implant. Laboratory bench testing confirmed that a minimum two-year implant longevity is highly probable with the current sensor design. The implant longevity was independently verified by a third-party using sensor parameters to simulate sensor performance over time. Given the positive results of the study, the Company is now preparing for long-term animal studies, which are expected to begin later this year.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 23,2023 TOP STORY

Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach)

The majority of people with type 2 diabetes who require insulin therapy use only basal insulin in combination with other anti-diabetic agents. The researchers tested whether using a smartphone application to titrate insulin could improve glycaemic control in people with type 2 diabetes who use basal insulin. This was a 12-week, multicentre, open-label, parallel, randomised controlled trial conducted in 36 diabetes practices in Germany. Participants in the intervention group titrated their basal insulin dose using a smartphone application (My Dose Coach) for 12 weeks. Control group participants titrated their basal insulin dose according to a written titration chart. The primary outcome was the baseline-adjusted change in HbA1c at 12 weeks. Between 13 July 2021 and 21 March 2022, 251 study participants were randomly assigned and 236 completed the follow-up phase. Study results suggest that utilizing this digital health smartphone application for basal insulin titration may have resulted in a comparatively greater reduction in HbA1c levels among individuals with type 2 diabetes, as compared to basal insulin titration guided by a written titration schedule.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 13,2023

Swimming With the Omnipod 5 Automated Insulin Delivery System: Connectivity in the Water

Swimming poses additional challenges for glycemic management with continuous glucose monitoring (CGM) and AID devices. The Omnipod 5 Automated Insulin Delivery System addresses this with a waterproof “Pod”. In the Omnipod 5 pivotal trial, some participants reported continued system function in the water. To investigate in-water system functionality, a single-center observational substudy was conducted from September 2021 until April 2022 among individuals in the Omnipod 5 pivotal extension study at Stanford University. The survey collected information related to swims, including measured interdevice distance and device placement on the body. On-body testing showed that communication success rates dropped off quickly with interdevice distances >13 cm. However, improved connectivity does not fully address glycemic control, which is also influenced by initial glucose at exercise start, circulating insulin levels, carbohydrate intake, and exercise intensity.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 19,2023

Impact of Continuous Glucose Monitoring Initiation on Emergency Health Services Utilization

The study assessed the effects of continuous glucose monitoring initiation (Dexcom) on emergency department (ED) visits in diabetes patients using insulin. Results from a large health insurer in the southeastern U.S. showed a 14% lower incidence rate of ED visits for CGM initiators compared to non-initiators.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 14,2023

Lark Health’s AI Coaching Drives Weight Loss Results in HPSAs

Lark Health conducted studies on their digital coaching programs, highlighting the positive outcomes in diabetes prevention. Their digital diabetes prevention program (DPP) reduced the risk of type 2 diabetes and promoted weight loss in underserved areas. Additionally, the program showed a decrease in depressive symptoms and improved engagement with the use of self-monitoring technologies.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

Alex Therapeutics presents major Eila clinical trial recruitment milestone

Alex Therapeutics, together with Pfizer, has reached the first major milestone in a clinical study of a digital therapeutic for the CBT-based treatment of tobacco dependence in Germany. The Eila study, number X9001304, is a prospective, comparative, randomized, single-blind, multicenter, pragmatic clinical study with approximately 1,000 participants in Germany, designed to assess the safety and effectiveness of the Eila® DTx compared to the standard of care. The medical device was developed by Alex Therapeutics and adapted to the requirements of the German healthcare system together with Pfizer. The partnership initially focuses on Germany, one of the world’s largest unified healthcare markets. 

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 21,2022

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

The Pilot study was a 4-week, single-arm, decentralized, open-label clinical investigation in 10 patients with self-reported anxiety related to idiopathic pulmonary fibrosis (IPF). The primary objective of the study was to test the functionality, user experience, and safety of the DTx, which were all found to be positive. Additionally, the trial provided encouraging early indications of efficacy. The patient-reported Generalized Anxiety Disorder (GAD-7*) results showed an average score reduction of 4.2. A reduction in the GAD-7 score of  ≥2 points is regarded as clinically meaningful. The full DTx, AlmeeTM, to which patients in this pilot were given limited access, has been developed by Alex Therapeutics in collaboration with Vicore Pharma.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 04,2023

AI and CRISPR Precisely Control Gene Expression

A study published in Nature Biotechnology demonstrates that artificial intelligence (AI) can accurately predict the on- and off-target activity of CRISPR tools that target RNA. The researchers combined deep learning with CRISPR screens to precisely control gene expression, offering potential for developing new CRISPR-based therapies. The AI model, called TIGER (Targeted Inhibition of Gene Expression via guide RNA design), outperformed previous models in predicting both on-target and off-target activity of RNA-targeting CRISPRs. The study highlights the potential of AI to enhance the development of RNA-targeting therapies in biomedicine, and to tackle the aberrant gene expressions seen in cancer, which leads to tumor growth.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 03,2023 TOP STORY

Study backs Lunit’s AI-powered cancer diagnostics

Lunit, a South Korean medical AI company, conducted a study published in the journal Radiology that demonstrated the effectiveness of its AI-powered cancer diagnostic solution. The study involved 30 doctors who analyzed 120 chest X-rays with and without the assistance of Lunit's AI model. The high-accuracy AI model significantly improved radiologists' performance, with an AUROC of 0.82 compared to 0.75 without AI. The study emphasized the importance of accurate AI models in enhancing diagnostic accuracy and fostering acceptance of AI in medical practices. Lunit aims to advance cancer diagnostics through innovative technology.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 29,2023

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study

Improved markers for predicting recurrence are needed to stratify patients with localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. The new study published on the Lancet Digital Health Journal presents a novel assay integrating three modalities—clinical, genomic, and histopathological—to improve the predictive accuracy for localised renal cell carcinoma recurrence. In this retrospective analysis and validation study, they developed a histopathological whole-slide image (WSI)-based score using deep learning allied to digital scanning of conventional haematoxylin and eosin-stained tumour tissue sections, to predict tumour recurrence in a development dataset of 651 patients with distinctly good or poor disease outcome. The multimodal recurrence score was validated in 1625 patients from the independent validation dataset and 418 patients from The Cancer Genome Atlas set. The primary outcome measured was the recurrence-free interval (RFI). The results of the study shows that multimodal recurrence score is a practical and reliable predictor that can add value to the current staging system for predicting localised renal cell carcinoma recurrence after surgery, and this combined approach more precisely informs treatment decisions about adjuvant therapy.

CLINICAL STUDY

#ml

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY